Aligos Therapeutics, Inc. (ALGS) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -23.13M | -21.75M | -24.34M | -15.5M | -20.91M | -18.4M | -20.1M | -19.49M | -22.75M | -22.66M | -20.34M | -13.62M |
| Operating CF Margin % | -817.24% | -12866.86% | -3285.43% | -1606.63% | -6723.15% | -2925.76% | -1584% | -1837.23% | -2306.9% | -845.13% | -627.85% | -197.73% |
| Operating CF Growth % | -10.61% | -18.16% | -21.11% | 20.46% | 8.08% | 18.78% | 1.16% | -43.16% | -1.6% | -35.01% | -18.67% | 45.61% |
| Net Income | -23.04M | -19.88M | -31.54M | -15.86M | 43.09M | -82.15M | -19.26M | 5.06M | -34.86M | -27.89M | -18.04M | -18.79M |
| Depreciation & Amortization | 346K | 257K | 220K | 259K | 510K | 671K | 667K | 610K | 674K | 775K | 681K | 769K |
| Stock-Based Compensation | 1.31M | 0 | 0 | 1.16M | 959K | 1.71M | 2.04M | 2.06M | 2.65M | 2.58M | 3.21M | 3.2M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -3.31M | 293K | 5.44M | -1.99M | -61.63M | 61.76M | -370K | -31.33M | 14.29M | 2.17M | 17K | 567K |
| Working Capital Changes | 1.56M | -2.41M | 1.53M | 930K | -3.83M | -390K | -3.18M | 4.11M | -5.49M | -293K | -6.2M | 643K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 3.66M | -669K | 752K | -402K | 1.73M | -169K | -4.08M | 3.98M | 325K | -423K | -300K | 419K |
| Cash from Investing | 34.93M | -2.02M | 47.68M | -39.42M | -44.07M | 19.97M | 10.4M | 39.99M | -88.64M | -7K | -9K | 25M |
| Capital Expenditures | -69K | -92K | -193K | -109K | -43K | -28K | -26K | -7K | -69K | -7K | -12K | 7K |
| CapEx % of Revenue | 2.44% | 54.44% | 26.05% | 11.3% | 13.83% | 4.45% | 2.05% | 0.66% | 7% | 0.26% | 0.37% | 0.1% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -7K | 7K |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | -62K | 123K | -53K | -177K | 101.74M | 97K | -4K | 281K | -19K | 87.94M | -21K | 414K |
| Debt Issued (Net) | -62K | -3K | -10K | -1K | 0 | -43K | -5K | -16K | -19K | -4K | -21K | -47K |
| Equity Issued (Net) | 0 | 126K | -43K | -176K | 101.74M | 0 | 1K | 0 | 0 | 87.94M | 0 | 461K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | 0 | 0 | 140K | 0 | 297K | 0 | 0 | 0 | 0 |
| Net Change in Cash | 11.74M | -23.64M | 23.29M | -55.1M | 36.77M | 1.67M | -9.71M | 20.78M | -111.41M | 65.27M | -20.37M | 11.8M |
| Free Cash Flow | -23.2M | -21.84M | -24.54M | -15.61M | -20.95M | -18.43M | -20.13M | -19.5M | -22.82M | -22.66M | -20.35M | -13.61M |
| FCF Margin % | -819.68% | -12921.3% | -3311.47% | -1617.93% | -6736.98% | -2930.21% | -1586.05% | -1837.89% | -2313.89% | -845.39% | -628.22% | -197.63% |
| FCF Growth % | -10.71% | -18.48% | -21.92% | 19.93% | 8.17% | 18.68% | 1.09% | -43.29% | -1.88% | -34.32% | -18.72% | 46.36% |
| FCF per Share | -2.23 | -2.10 | -2.37 | -1.51 | -2.41 | -2.93 | -3.21 | -3.11 | -1.47 | -0.91 | -0.47 | -0.31 |
| FCF Conversion (FCF/Net Income) | 1.00x | 1.09x | 0.77x | 0.98x | -0.49x | 0.22x | 1.04x | -3.85x | 0.65x | 0.81x | 1.13x | 0.72x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |